Sanotize Research and Development Corp.   Report issue

For profit Phase 2 Phase 3
Founded: Vancouver Canada (2017)

Organization Overview

First Clinical Trial
2019
NCT04163978
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

SaNOtize R&D Corp | Sanotize Research and Development corp.

Active Ingredients

Drugs in Phase 3 Trials (1)

nitric oxide (inomax) (8 trials)

Drugs in Phase 2 Trials (1)

budesonide (rhinocort) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Sinusitis (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 2